Special offer ticket price extended until midnight EDT today! Join us for two action-packed days of aging research and biotech business talks in the heart of New York City. Use the code: Metchnikoff to get $50 off the ticket cost today.
Find out more here: https://www.eventbrite.com/e/ending-age-related-diseases-20…
Stanford University School of Medicine scientists have definitively linked mast cells, a class of cells belonging to the immune system, to the development of osteoarthritis, one of the world’s most common causes of pain and immobility.
In a study published online May 14 in eLife, the scientists demonstrated for the first time that banishing mast cells—or blocking signals from the most common stimulus activating them in real life, or disabling a cartilage-degrading enzyme they release when activated—all protected mice from developing osteoarthritis typically induced by a classic experimental procedure. The results were supported by findings in human cells and tissues.
Osteoarthritis, by far the most frequently occurring variety of arthritis, is characterized by cartilage breakdown and inflammation in joints, which can be further aggravated by excess bone growths called osteophytes.
A sensational new study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development. The study reveals that the destiny of intestinal cells is not predetermined, but instead determined by the cells’ surroundings. The new knowledge may make it easier to manipulate stem cells for stem cell therapy. The results have been published in Nature.
All cells in the foetal gut have the potential to develop into stem cells, a new study conducted at the Faculty of Health and Medical Sciences at the University of Copenhagen concludes. The researchers behind the study have discovered that the development of immature intestinal cells—contrary to previous assumptions—is not predetermined, but affected by the cells’ immediate surroundings in the intestines. This discovery may ease the path to effective stem cell therapy, says Associate Professor Kim Jensen from the Biotech Research & Innovation Centre (BRIC) and the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem).
“We used to believe that a cell’s potential for becoming a stem cell was predetermined, but our new results show that all immature cells have the same probability for becoming stem cells in the fully developed organ. In principle, it is simply a matter of being in the right place at the right time. Here signals from the cells’ surroundings determine their fate. If we are able to identify the signals that are necessary for the immature cell to develop into a stem cell, it will be easier for us to manipulate cells in the wanted direction.”
Your mother was right: Broccoli is good for you. Long associated with decreased risk of cancer, broccoli and other cruciferous vegetables—the family of plants that also includes cauliflower, cabbage, collard greens, Brussels sprouts and kale—contain a molecule that inactivates a gene known to play a role in a variety of common human cancers. In a new paper published today in Science, researchers, led by Pier Paolo Pandolfi, MD, Ph.D., Director of the Cancer Center and Cancer Research Institute at Beth Israel Deaconess Medical Center, demonstrate that targeting the gene, known as WWP1, with the ingredient found in broccoli suppressed tumor growth in cancer-prone lab animals.
“We found a new important player that drives a pathway critical to the development of cancer, an enzyme that can be inhibited with a natural compound found in broccoli and other cruciferous vegetables,” said Pandolfi. “This pathway emerges not only as a regulator for tumor growth control, but also as an Achilles’ heel we can target with therapeutic options.”
A well-known and potent tumor suppressive gene, PTEN is one of the most frequently mutated, deleted, down-regulated or silenced tumor suppressor genes in human cancers. Certain inherited PTEN mutations can cause syndromes characterized by cancer susceptibility and developmental defects. But because complete loss of the gene triggers an irreversible and potent failsafe mechanism that halts proliferation of cancer cells, both copies of the gene (humans have two copies of each gene; one from each parent) are rarely affected. Instead, tumor cells exhibit lower levels of PTEN, raising the question whether restoring PTEN activity to normal levels in the cancer setting can unleash the gene’s tumor suppressive activity.
Silicon transistors and the brain don’t mix.
At least not optimally. As scientists and companies are increasingly exploring ways to interface your brain with computers, fashioning new hardware that conforms to and compliments our biological wetware becomes increasingly important.
To be fair, silicon transistors, when made into electrode arrays, can perform the basics: record neural signals, process and analyze them with increasingly sophisticated programs that detect patterns, which in turn can be used to stimulate the brain or control smart prosthetics.
In coming years, scientists plan to grow human embryos in a lab using high-tech artificial wombs.
Doctors at the Children’s Hospital of Philadelphia are in talks with the U.S. Food and Drug Administration (FDA) to begin testing artificial wombs on human embryos within the next two years, according to Metro. If they’re successful, the research could radically change the way we view pregnancy, childbirth, and perhaps even human evolution.
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a material that can significantly extend the life of batteries and afford them higher capacities, as well.
From smartphones to pacemakers and cars, batteries power much of our world and their importance only continues to grow. There are two particular aspects of batteries that many believe need to improve to meet our future needs. These are the longevity of the battery and also its capacity—how much charge it can store.
The chances are your devices use a type of battery called a lithium-ion battery. But another kind based on sodium rather than lithium may become commonplace soon. Both kinds of battery can store and deliver a large amount of charge, thanks to the way constituent materials pass electrons around. But in both lithium and in sodium batteries, repeated cycles of charging and usage can significantly reduce the storage capacity over time.
University at Buffalo researchers have identified the first human-specific fusion gene—a hybrid of two genes—implicated in Alzheimer’s disease. The finding suggests that a neurotransmitter receptor, previously successful in animal studies but that failed in human trials for Alzheimer’s, might still turn out to be a valuable therapy.
In a paper published in February in Translational Psychiatry, the UB researchers reported that this human fusion gene acts on a receptor for the neurotransmitter acetylcholine, which is involved in memory and learning, and which is reduced in people with Alzheimer’s.
The fusion gene is CHRFAM7A, which is very common in people and has been implicated in many neuropsychiatric disorders, such as schizophrenia and bipolar disease.
MIT professor Sangeeta Bhatia is currently devising a simple urine test that works just like a pregnancy test to detect cancer the moment it starts. In this video, Big Think contributor Susan Hockfield, president emerita of MIT, explains how the new technology works.
